Management team

• 

  Yusheng Wu, Ph.D.

  Chair/CEO/Founder

  Ph.D., Iowa State University

  Postdoc, California Institute of Technology

  Dr. Wu served as Senior fellow/project manager at Schering-Plough with 20+ years of experience in experience in the pharmaceutical industry, with pioneering contributions in the development of new drugs for oncology, cardiovascular disease, diabetes, obesity, Alzheimer’s disease, etc. Over years, Dr. Wu has published 100+ peer reviewed research articles and obtained 50+ issued US/EU/Chinese patents

  Awards

  New Jersey Minority Contribution Award, 2005

  Schering-Plough research & development president’s award, 2016

  National Distinguished Expert, China, 2012

• 

  Shaoqing Chen, Ph.D.

  Senior Vice President/Medicinal Chemistry

  Ph.D., Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences

  Postdoc, University of Pittsburgh and Scripps Research Institute

  Dr. Chen has successively served as the senior executive in well-known domestic and multinational pharmaceutical companies, such as Versicor Pharmaceuticals, Roche Pharmaceuticals, Furen Medicines, etc. He has over 25 years of experience in new drug research and development, with expertise in areas such as oncology, diabetes,  antivirals, autoimmune diseases, and antibiotics with extensive international experience in new drug R&D and project management

  Published nearly 30 peer-reviewed research articles

  Obtained nearly 40 issued US/EU/Chinese patents

• 

  Xiugui Chen

  Senior Vice President/Medical and Registration Affairs

  M.Med, Shanghai University of Traditional Chinese Medicine

  5 years of clinical experience as an attending physician.

  Before joining TYK Medicines, Mr. Chen served as medical manager at Betta Pharmaceutical, medical development director at Ascletis Pharma Inc and Yangtze River Pharmaceutical Group, and chief engineer assistant/clinical pharmacology center director at Minsheng Pharma.

  With over 20 years of experience in clinical development and registration of new drugs, Mr. Chen has in-depth knowledge of clinical development strategy, clinical trial design, clinical trial execution, and clinical operations in the fields of oncology, liver diseases, hematology, digestive diseases, and skin diseases. He has directly led or participated in the clinical development and registration for marketing of 10+ innovative drugs, including Icotinib, Ensartinib, Danoprevir, and Acetylcysteine Injection, which have been marketed in China.

• 

  Mingyu Jiang, Ph.D.

  Secretary of the Board of Directors

  PhD in Pharmacy, China Pharmaceutical University

  Master in Finance, Fordham University

   

  FRM Charter Holder

   

  2009-2011 KPMG, Auditor

  2011-2013 KPMG, Consultant

  2015-2018 Shanghai Pudong Science and Technology Investment Co., Ltd, Risk Manager

  2018-2019 Zheshang Securities Co., Ltd, Senior Research Fellow

  2019-present TYK Medicines Inc, Secretary of the Board of Directors

  Independently lead Investment&Financing Department, accomplish billion level equity financing.

  Independently lead series of new drug M&A projects and license-out projects worth of hundred million level.